Equity Overview
Price & Market Data
Price: $0.82
Daily Change: +$0.023 / 2.81%
Range: $0.82 - $0.82
Market Cap: $2,676,372
Volume: 831
Performance Metrics
1 Week: -26.23%
1 Month: 32.35%
3 Months: 17.49%
6 Months: -77.50%
1 Year: -87.16%
YTD: -4.43%
Company Details
Employees: 27
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate is pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. It is developing Pepinemab, which is in phase 2 study for the treatment of Alzheimer's disease and has completed phase 2 study for the treatment of Huntington's disease; Pepinemab in combination with Pembrolizumab in phase 2 study for head and neck cancer, Avelumab in phase 2 study for pancreatic cancer, and completed phase 2 study with Avelumab for non-small cell lung cancer; Pepinemab in combination with Nivolumab completed phase 2 study for melanoma; and trastuzumab and dendritic cell vaccines in phase 2 study for breast cancer. The company has also developed ActivMAb, an antibody drug discovery platform based on a novel method for complex targets, such as multi-pass membrane receptors or large and diverse libraries of full-length human monoclonal antibodies on the surface of pox viruses. It has collaborations with Merck Sharp & Dohme; Ares Trading S.A.; The Children's Hospital of Philadelphia; Emory University; Huntington Study Group; Catalent Pharma Solutions, LLC; and Surface Oncology, Inc. The company was incorporated in 2001 and is headquartered in Rochester, New York.